Whole-genome scan association analysis was carried out to identify genetic variants predictive of lung cancer risk in smokers and to confirm the identified variants in an independent sample.
INTRODUCTION
Lung cancer is the leading cause of cancer mortality in the Western world. Indeed, this malignancy has a poor prognosis and, so far, therapeutic strategies have shown only a limited effect. Lung cancer risk is strongly associated with exposure to environmental carcinogens, in particular to cigarette smoke. Nevertheless, only approximately 10% of smokers develop lung cancer, and the disease also occurs in the absence of exposure to cigarette smoke. Therefore, the potential role of hereditary components in determining the risk of lung cancer in smokers should not be underestimated. Although this hypothesis has been questioned in some studies, 1 epidemiologic data support the presence of genetic risk factors in lung cancer. [2] [3] [4] [5] [6] [7] Whole-genome analyses in mouse models have identified genetic loci that affect lung cancer risk. Indeed, genetic analysis of these models provided evidence of a complex inheritance of genetic predisposition to lung tumorigenesis 8 and suggested that polygenic inheritance of predisposition to cancer might also occur in humans. 9 In mice, whole-genome analyses require only a few hundred genetic markers because of the genetic homogeneity of inbred strains, the limited number of genetic recombinations in crosses, and the consequent tight linkage of genetic markers over wide chromosomal regions. 8 Because of the genetic heterogeneity of the human population, complete analysis of the human genome by association studies may require a huge number of genetic markers and large sample collections. However, the presence of haplotype blocks in the human genome 10 suggests that even a less dense marker coverage might be sufficient for a whole-genome analysis. Although the characterization of these haplotype blocks awaits completion, 11 population-based association studies are complicated by complex linkage disequilibrium (LD) patterns, possible population admixture in the selection of cases or controls, differences in environmental factors, and other factors.
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In an effort to identify genetic variants that may predict individual risk of lung cancer in smokers, we conducted a large-scale case-control study using more than 80,000 single nucleotide polymorphisms (SNPs) located primarily in gene-based regions. We report the identification of an 80-kb genomic region on chromosome 19q12-q13.1 including the programmed cell death 5 gene (PDCD5, also called TFAR19 [TF1 cell apoptosis-related gene 19]) that conferred increased lung cancer risk in two independent sample collections and that may predict disease outcome.
PATIENTS AND METHODS

Patients and Tissue Samples
The initial study included 322 male smokers with lung cancer who were recruited at the Pneumology and Thoracic Surgery Clinics in StuttgartGerlingen and the Pneumology Clinic in Munich-Gauting (both in Germany), and 273 healthy smokers recruited at the same sites and at the Dermatology Department of the University Hospital in Tuebingen, Germany ( Table 1) . The Italian replication sample included 254 cases of pathologically documented lung adenocarcinoma (ADCA) patients who underwent surgery at Istituto Nazionale Tumori (Milan, Italy), and 235 healthy controls (blood donors) enrolled at the same institute. Personal files were recorded to obtain clinical data (Tables 1 and 2 ). All subjects involved in our studies signed a written informed consent, and the institutional ethics committees of participating institutions approved the study protocol.
For the German discovery samples, DNA was obtained from blood samples using a desalting method (Gentra Systems, Minneapolis, MN) and quantitated using Pico green reagents and a Fluorometer (Fluoroskan Ascent CF; Labsystems, Chicago, IL). Genomic DNAs of the Italian patients and controls were extracted from a small piece of nontumor tissue excised during surgery or from peripheral blood samples using the automatic DNA extractor Extragen 8C (Talent, Trieste, Italy).
Total RNA was extracted from 20 paired nontumor lung parenchyma and lung tumor tissue and additional 26 nontumor lung parenchyma of Italian lung ADCA patients using RNeasy Midi kit (Qiagen, Valencia, CA). cDNA was synthesized from RNA of each sample using the SuperScript First-Strand Synthesis System (Invitrogen, Carlsbad, CA).
SNP Markers and Genotyping
A set of 83,715 SNP markers was selected from a collection of 125,799 experimentally validated polymorphic variations. 13 This set was limited to SNPs located within gene coding regions, with minor allele frequencies greater than 0.02 (95% have frequencies greater than 0.05) and a median intermarker spacing of 15 kb. SNP annotation is based on the National Center for Biotechnology Information (NCBI; www.ncbi.nlm.nih.gov/) dbSNP database, ref-SNP, Build 118. Genomic annotation is based on NCBI Genome Build 34. Gene annotation is based on Entrez Gene entries for which NCBI provided positions on the Mapview FTP site.
DNA pools were formed by combining equimolar amounts of each sample as described.
14 For pooled DNA assays, 25 ng of case and control DNA pools was used for amplification at each site. All polymerase chain reaction (PCR) and homogeneous MassEXTEND 15 reactions were conducted using standard conditions. Relative allele frequency was estimated on the basis of the area under the peak calculated from mass spectrometry measurements of four aliquots, as described. 15 For individual genotyping, the same procedure was applied with the following differences: only 2.5 ng DNA was used and only one mass spectrometry measurement was taken.
The following gene-specific primers were used to genotype the marker SNP rs1862214: PCR primer 1-5Ј-ACGTTGGATGCCTGTTTTCCTGAT-CACACC-3Ј; PCR primer 2-5Ј-ACGTTGGATGTGCAGTCCTGAAAG-GAAACC-3Ј; extension primer-5Ј-CACACCACTCACTGCAC-3Ј.
Cloning of PDCD5 From Human Lung Tissue
Primers5Ј-GAGCCATGGCGGACGAGGAGC-3Јand5Ј-ATAATCGT-CATCTTCATCAGAG-3Ј were used for amplification of the human PDCD5 gene from lung tissue. Total RNA from nontumor lung parenchyma of two lung cancer patients was reverse-transcribed using ThermoScript (Invitrogen). PCR amplification was carried out in 50-L volume containing aliquots of healthy lung cDNA, 100 mol/L deoxynucleotide triphosphates, 15 pmol gene-specific primers, 1.5 mmol/L MgCl 2 , and 0.6 U Amplitaq Gold DNA polymerase (Applied Biosystems, Foster City, CA). Cycling conditions were 20 seconds at 94°C, 20 seconds at 55°C, and 60 seconds at 72°C for 40 cycles. Amplified products in aliquots were subcloned into pEF6/V5-His TOPO vector (Invitrogen, Carlsbad, CA) in-frame with the V5 epitope and polyhistidine tag. Clones were screened and sequenced using vector-specific primers.
Real-Time Quantitative PCR
Expression of PDCD5 mRNA was quantitated by kinetic reversetranscriptase PCR using Hs00270435_m1 TaqMan Gene Expression Assayon-Demand (Applied Biosystems). The real-time PCR amplification mixture contained 1 L cDNA template; 10 L 2ϫ TaqMan Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems); and 1 L of 20ϫ Assay-onDemand Gene Expression Assay Mix (Applied Biosystems). The final volume was adjusted to 20 L with Rnase-free water. Reactions were run in duplicate on an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) for 40 cycles (95°C for 15 seconds, 60°C for 1 minute) after initial activation steps at 50°C for 2 minutes and 95°C for 10 minutes. The experiment was carried out in duplicate. The human hydroxymethylbilane synthase (HMBS) gene (Hs00609297_m1 TaqMan Gene Expression Assay-on-Demand) was used as control for possible differences in cDNA amounts. Relative differences (-fold) were calculated according to the comparative Ct (cycle at which the amplification plot crosses the threshold) method.
Transfection and In Vitro Clonogenic Assay
Human cell lines A549 and NCI-H520, derived from lung carcinoma and lung squamous cell carcinoma, respectively, were transfected with 2.5 g DNA of recombinant or control vector (pEF6/V5-His-TOPO) using SuperFect Transfection Reagent (Qiagen) and Nupherin-neuron (Biomol, Plymouth Meeting, PA). Transfected clones were selected with blasticidin 5 g/mL (Invitrogen) for 3 (A549) or 4 (NCI-H520) weeks, methanol-fixed and stained with 10% giemsa. The clonogenic assay was carried out in selective medium containing 10% serum; additionally, A549 cells were tested in low-serum (0.5% fetal bovine serum) medium.
Statistical Analysis
Association between disease status and each SNP using pooled DNA was tested as described. 16 Sources of measurement variation included pool formation, PCR/mass extension, and chip measurement. When three or more replicate measurements of an SNP were available within a model level, the corresponding variance component was estimated from the data. Otherwise, the following historical laboratory averages were used: pool formation ϭ 5.0 ϫ 10 . The Hardy-Weinberg equilibrium was tested by the 2 method. 17 Logistic regression was used to compute odds ratios (ORs) and 95% CIs. The KaplanMeier product-limit method, the log-rank test, 18, 19 and the Cox regression model were used to evaluate the effect of the PDCD5 genotype on overall survival. The Kruskal-Wallis test was used to assess the association between genotype and age at cancer onset and to analyze mRNA levels of the PDCD5 gene, as well as cell colony formation data.
RESULTS
Identification of a Lung Cancer Susceptibility Locus on 19q12-q13.1
Using a screening strategy based on DNA pooling, 20,21 we examined DNA samples from 322 German smokers clinically diagnosed with lung cancer and 273 age-matched healthy smokers (Tables 1 and  2 ) in a genome-wide study consisting of 83,715 SNPs. Individual genotyping identified 160 SNPs that differed significantly (P Ͻ .05) between cases and controls. To verify true genetic effects by independent replication, we also studied a group of 254 Italian lung cancer patients and 235 unaffected controls.
One of the loci identified was located on chromosome 19q12-q13.1. A C/G polymorphism (rs1862214) located 35 kb upstream of the PDCD5 gene was associated with lung cancer susceptibility. Analysis of the German discovery sample revealed an increased frequency of the rare G allele in lung cancer patients (0.29) as compared with controls (0.22; Table 3 ). Frequencies of the CG and GG genotypes were higher among patients (41% and 9%, respectively) than controls (37% and 3%, respectively). Hardy-Weinberg genotypic proportions were taken into account for in both groups (Table 3) . A significant association with lung cancer risk was found in the discovery set of cases, with an OR for GG homozygous versus CC homozygous patients of 3.5 (95% CI, 1.3 to 9.5; Table 3 ). Whereas comparison of the common CC genotype with CG heterozygous or with the G allele carrier status revealed no statistically significant associations, the relative ORs were more than 1 (Table 3 ). In this sample, the presence of 32% female controls and the lack of matched female cases might have decreased the statistical association. Indeed, logistic analysis without sex adjustment indicated a significant association for the G allele carrier status (OR, 1.4; 95% CI, 1.03 to 2.01), and the homozygous comparison (GG v CC) showed a stronger association in the sexunadjusted (data not shown) than in the sex-adjusted analysis.
Frequencies of the susceptibility G allele were similar in the control groups of both discovery and replication samples (0.22; Table 3 ). The frequency of the G allele was also increased in Italian lung cancer patients (0.27), with a detected OR of 2.1 (95% CI, 1.3 to 3.3) for patients carrying the G allele (GG or CG) as compared with CC homozygous patients (Table 3) . A combined analysis of the two samples resulted in an OR of 1.6 (95% CI, 1.2 to 2.1; P ϭ .0004) for individuals carrying the G allele (Table 3) . A trend toward an increased risk was observed from heterozygous to homozygous patients carrying the rare allele, with ORs of 1.5 (95% CI, 1.1 to 2.0) and 2.9 (95% CI, 1.5 to 5.7), respectively (Table 3) .
LD in the PDCD5 Gene Region
To fine-map the region of association, we tested 44 additional SNPs located within 50 kb to either side of the PDCD5 gene using the discovery pools (Fig 1) . Sixteen of the 45 SNPs tested were significantly associated with lung cancer risk (P Ͻ .05). The region of highest significance spanned approximately 80 kb and included the PDCD5 gene and the 3Ј end of the ankyrin repeat domain 27 (VPS9 domain) ANKRD27 gene (Fig 1A) . This is in agreement with data from the CEPH30 sample from the HapMap project 11 and confirms the determined LD block (Fig 1B) . Little is known about the biologic functions of the ANKRD27 gene, whereas the PDCD5 gene is known to be involved in apoptosis, 22 and is therefore a likely candidate for the observed effect on lung cancer risk.
Association of rs1862214 SNP With Lung Cancer Prognosis
Analysis of the rs1862214 polymorphism with respect to prognostic factors in Italian lung cancer patients revealed a significant positive association between the rare G allele and advanced clinical stage, nodal status, or overall survival. Indeed, the allele G carrier status showed a significant association with higher clinical stages (hazard ratio [HR], 1.9; 95% CI, 1.1 to 3.4; P ϭ .023). The association was statistically significant alsofortheheterozygousgenotypegroup(HR,1.9;95%CI,1.1to3.4; Pϭ .028) but not for the GG homozygous group (HR, 3.3; 95% CI, 0.7 to 15.3). Although the HR was higher in the latter group, the lack of association might be due to the low number of patients with the GG genotype and the small number of events detected in this group (Table 4) .
Presence of lymph node metastases was more frequent in patients carrying the G allele than in CC homozygous patients (HR, 1.9; 95% CI, 1.1 to 3.6; P ϭ .033), and the CG and GG groups maintained an excess value over CC homozygous patients, although the statistical significance was borderline (P ϭ .054 and P ϭ .051, respectively; Table 4 ). Median follow-up of patients alive at the end of the follow-up period was 56.5 months (Table 2) . Kaplan-Meier survival curves analysis showed a significant difference among the three genotype groups (log-rank P ϭ .0013), with median survival times of 79.8, 40.2, and 19.0 months associated with the CC, CG, and GG genotypes, respectively (Fig 2) . Cox proportional hazard analysis of survival, adjusted for sex, smoking habits, and age at diagnosis (in decades) showed that patients carrying the CG and GG genotype had a poorer survival than patients with the CC genotype, with a trend in excess HR associated with copy number of the G allele (HR, 1.7; 95% CI, 1.2 to 2.5; P ϭ .007 for the CG genotype and HR, 2.4; 95% CI, 1.1 to 5.6; P ϭ .034 for the GG genotype; Table 4 ). Overall comparison of patients carrying the G allele (at homozygosity or heterozygosity) versus CC homozygous patients revealed a significant excess of deaths associated with the G allele carrier status (HR, 1.8; 95% CI, 1.2 to 2.6; P ϭ .003; Table 4) , with a median follow-up at death of 40.2 months for the G allele carriers and of 79.8 months for CC homozygous ADCA patients.
PDCD5 mRNA Expression Is Downregulated in Lung Cancer
Because genomic DNA and RNA were available from nontumor and tumor lung tissue of 46 Italian lung adenocarcinoma patients, samples with different rs1862214 genotypes (24 CC, 17 CG, and five GG) were analyzed for PDCD5 expression to identify a possible correlation between SNP genotypes and mRNA levels. However, the mRNA levels in healthy lung tissue were similar in the common CC genotype as compared with G-allele carriers (data not shown). Differences between nontumor and tumor tissue in PDCD5 mRNA levels did not correlate with the genotype at the rs1862214 polymorphism (data not shown).
PDCD5 Overexpression Inhibits Colony Formation In Vitro
Amplification of the PDCD5 gene from human lung cDNA produced two different transcripts: the annotated variant NM_004708, consisting of six exons and encoding a protein of 125 amino acids, and an additional alternatively spliced variant that lacks exons 3 to 5 and is translated into a truncated protein product of 40 residues (GenBank Access No. DQ208400; http://www.ncbi.nlm.nih.gov/Genbank/). Mammalian expression vectors containing PDCD5 isoforms were prepared and transfected into A549 and NCI-H520 human lung cancer cell lines, whose endogenous levels of PDCD5 mRNA were approximately 0.8-and 0.3-fold lower, respectively, as compared with a pool of healthy lung tissue from 20 patients (data not shown). Overexpression of either PDCD5 transcript in the human lung cancer cell line A549 did not lead to significant variation in number or size of colonies grown in both high-and low-serum conditions (data not shown). By contrast, a significant inhibitory effect on colony formation was observed in NCI-H520 cells, with the number of colonies more than 0.5 mm in diameter approximately 6-fold lower (Pϭ.006) in cells transfected with the full-length PDCD5 transcript than in control cells (Fig 4A and B) . Cells overexpressing the short PDCD5 variant showed an approximately 1.5-fold reduction in clonogenicity, but the difference from the vector-transfected cells was not statistically significant (Fig 4A and B) .
DISCUSSION
Genetic loci affecting lung cancer risk have been identified in mouse models, but the relationship with the risk of human lung cancer has The curves of patients with PDCD5 genotype CC (n ϭ 108), CG (n ϭ 98), or GG (n ϭ 10) are shown as orange, blue, and pink lines, respectively. Follow-up is shown truncated at 60 months. Small crosses indicate censored observations. Log-rank analysis indicates significant differences between curves (P ϭ .0013). not yet been established. One reason for the gap between the characterization of genetic factors involved in this disease in humans and experimental models is the difficulty in carrying out family-based studies for lung cancer because this disease rarely clusters in families and has a poor prognosis, making a sib-pair study design difficult. The strong association of lung cancer risk with smoking habits further complicates family-based linkage studies.
Despite these difficulties, a recent genetic linkage study in lung cancer families reported a significant linkage of a single locus on chromosome 6q23-25 to lung cancer risk. 23 This result supports the idea that genetic factors influence lung cancer risk in humans, but does not rule out a potential polygenic mode of inheritance of such risk, in analogy with the mouse model. Indeed, the observation of a single locus linked to lung cancer risk may simply reflect the relatively low power of that study to detect additional loci. Because the study in pedigrees included rare families with multiple lung cancer cases, whereas the large majority of lung cancer cases occur without familial clustering, the role of this locus in nonfamilial lung cancer by population-based association studies remains to be established.
In our present genome-wide association study, we identified several chromosomal regions putatively associated with lung cancer risk in smokers. Replication of these findings in an independent sample for which follow-up data were available verified the validity of the observed associations and their importance in different populations. We identified a significant association of a SNP on chromosome 19, 35 kb 5Ј of the PDCD5 gene, with lung cancer risk. The association was first observed in a collection of German lung cancer cases consisting only of male smokers with a range of histologic subtypes and later confirmed in an independent population of Italian lung ADCA patients of both sexes, with mixed smoking habits. Despite the heterogeneity of the discovery and replication samples, the significant association between the rs1862214 SNP and lung cancer risk in both populations points to an important role for this chromosomal region in lung cancer predisposition. Moreover, in the replication sample, the same allele (G) associated with an increased lung cancer risk (Table 3) was also associated with poor survival, higher clinical stage, and nodal involvement (Table 4 ). This finding further supports the involvement of the PDCD5 region in the etiology of lung cancer.
The rs1862214 variation is part of a haplotype block that contains the PDCD5 gene. This gene is a strong candidate for the modulation of lung cancer risk because of its described biologic functions and its involvement in the regulation of cell apoptosis. Indeed, PDCD5 levels are significantly increased in cells undergoing apoptosis, and the rapid translocation of the protein from the cytoplasm to the nucleus of apoptotic cells precedes the externalization of phosphatidylserine and the fragmentation of chromosome DNA. 24 Moreover, the introduction of anti-PDCD5 antibody suppresses apoptosis, 25 supporting the critical role of PDCD5 in this pathway.
Since transcription may also be affected by long-range regulatory sequences, we investigated whether the rs1862214 SNP, which is 35 kb upstream of the PDCD5 gene, has a functional role in PDCD5 mRNA expression in normal and tumor lung tissue. However, in healthy lung parenchyma PDCD5 mRNA levels were similar in individuals with the common CC genotype as compared with G-allele carriers.
Preliminary functional studies in vitro using human lung cancer cell lines transfected with recombinant mammalian expression vectors for the PDCD5 gene indicated that overexpression of this gene significantly inhibits colony growth in NCI-H520 cells but does not modulate colony formation in A549 cells. The reasons for such cell-specific effect are not known. Perhaps the ability of PDCD5 in modulating clonogenicity may be related to specific somatic alterations of cancer cells.
Analysis of a shorter mRNA variant encoding only the 40 N-terminal amino acid residues of PDCD5 in NCI-H520 cells showed that the inhibitory activity of PDCD5 is almost completely lost, indicating that important functional domains are present in the truncated portion. However, mRNA levels of this shorter transcript were approximately 10-fold lower than those of the full-length variant in nontumor lung tissue, and the relative quantity of the two isoforms did not differ in lung tumor tissue (data not shown). Additional studies, including silencing of the PDCD5 gene and studies in animal models, may provide further insight into the role of PDCD5 in lung cancer risk and development. 
